Matches in SemOpenAlex for { <https://semopenalex.org/work/W3138360445> ?p ?o ?g. }
Showing items 1 to 32 of
32
with 100 items per page.
- W3138360445 abstract "The problem of early diagnostics and prevention of cervical cancer is actual in Ukraine.The leading etiologic factor in the genesis of cervical neoplasia and a number of other organs is Human papillomavirus (HPV). The human papillomavirus is sexually transmitted and has high contagiosity. Cancer prevention consists in effective screening, early detection and treatment of pathological changes in the cervix. The aggressive treatment of diseases caused by (HPV) has been replaced by a tactic of a differentiated approach, taking into account to the age of the woman and her reproductive plans. The objective: was to study the efficacy and tolerability of the combined use of Proteflazid® systemically in drops form and locally in the form of suppositories for 3 months in patients with cervical intraepithelial neoplasia (CIN) of lung and moderate severity (CIN 1 and CIN 2) associated with the human papillomavirus (HPV); determination on the basis of the results of the need for further destructive treatment. Materials and methods. For the period from July 2016 to September 2017, we examined and treated 86 women with morphologically confirmed intraepithelial neoplasia of the cervix associated with HPV infection. Results. Based on the performed studies, it was found that 6 months after treatment with Proteplasid® systemically and locally for 3 months, regression of CIN was noted in 93% of patients. In all cases, a reduction in viral load of more than 2 Lg of HPV/105, which is a marker of the effectiveness of antiviral therapy, has been recorded. Six months after treatment in 84% of patients and 9 months in 88%, there was complete elimination of HPV or reduced viral load to clinically insignificant values – less than 3 Lg. Conclusion. The drug Proteflazid® suppositories and drops contributes to the elimination of human papillomavirus (HPV) and other viral-bacterial infections and reduces the risk of cervical neoplasia. Key words: cervical cancer, screening, cervical neoplasia, Human papillomavirus, viral-bacterial infections, Proteflazid®." @default.
- W3138360445 created "2021-03-29" @default.
- W3138360445 creator A5005022271 @default.
- W3138360445 creator A5091188231 @default.
- W3138360445 date "2017-11-30" @default.
- W3138360445 modified "2023-09-24" @default.
- W3138360445 title "The ways of reducing diagnostic and therapeutic aggression of the patients with HPV-infection in reproductive age" @default.
- W3138360445 doi "https://doi.org/10.15574/hw.2017.125.51" @default.
- W3138360445 hasPublicationYear "2017" @default.
- W3138360445 type Work @default.
- W3138360445 sameAs 3138360445 @default.
- W3138360445 citedByCount "0" @default.
- W3138360445 crossrefType "journal-article" @default.
- W3138360445 hasAuthorship W3138360445A5005022271 @default.
- W3138360445 hasAuthorship W3138360445A5091188231 @default.
- W3138360445 hasConcept C118552586 @default.
- W3138360445 hasConcept C15744967 @default.
- W3138360445 hasConcept C177713679 @default.
- W3138360445 hasConcept C2779448149 @default.
- W3138360445 hasConcept C71924100 @default.
- W3138360445 hasConceptScore W3138360445C118552586 @default.
- W3138360445 hasConceptScore W3138360445C15744967 @default.
- W3138360445 hasConceptScore W3138360445C177713679 @default.
- W3138360445 hasConceptScore W3138360445C2779448149 @default.
- W3138360445 hasConceptScore W3138360445C71924100 @default.
- W3138360445 hasLocation W31383604451 @default.
- W3138360445 hasOpenAccess W3138360445 @default.
- W3138360445 hasPrimaryLocation W31383604451 @default.
- W3138360445 isParatext "false" @default.
- W3138360445 isRetracted "false" @default.
- W3138360445 magId "3138360445" @default.
- W3138360445 workType "article" @default.